Profile data is unavailable for this security.
About the company
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
- Revenue in USD (TTM)0.00
- Net income in USD-746.61m
- Incorporated--
- Employees239.00
- LocationBiohaven Ltd215 Church StreetNEW HAVEN 06510United StatesUSA
- Phone+1 (203) 404-0410
- Websitehttps://www.biohaven.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guardant Health Inc | 643.81m | -490.76m | 3.09bn | 1.78k | -- | -- | -- | 4.79 | -4.09 | -4.09 | 5.36 | -0.0131 | 0.3733 | 4.04 | 6.89 | 361,894.30 | -28.46 | -22.26 | -32.21 | -24.59 | 59.95 | 64.62 | -76.23 | -97.07 | 6.07 | -10.18 | 1.00 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Iovance Biotherapeutics Inc | 32.77m | -440.22m | 3.09bn | 557.00 | -- | 3.93 | -- | 94.19 | -1.68 | -1.68 | 0.1245 | 2.59 | 0.0381 | 2.40 | 2.07 | 58,836.63 | -51.14 | -51.47 | -57.20 | -57.56 | -37.43 | -- | -1,343.27 | -137,873.80 | 4.85 | -- | 0.0013 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Apogee Therapeutics Inc | 0.00 | -118.49m | 3.12bn | 91.00 | -- | 3.91 | -- | -- | -2.25 | -2.25 | 0.00 | 13.65 | 0.00 | -- | -- | 0.00 | -25.44 | -- | -26.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Amicus Therapeutics, Inc. | 455.66m | -119.54m | 3.24bn | 517.00 | -- | 24.40 | -- | 7.10 | -0.397 | -0.397 | 1.51 | 0.4471 | 0.6159 | 0.6948 | 6.12 | 881,344.30 | -16.16 | -30.65 | -20.75 | -36.55 | 89.88 | 88.94 | -26.23 | -86.10 | 2.26 | -0.6134 | 0.7459 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Rhythm Pharmaceuticals Inc | 101.78m | -260.73m | 3.28bn | 226.00 | -- | 83.30 | -- | 32.22 | -4.37 | -4.37 | 1.71 | 2.94 | 0.2943 | 1.25 | 6.48 | 450,367.30 | -75.00 | -47.21 | -87.80 | -52.84 | 88.80 | -- | -254.88 | -681.38 | 6.31 | -- | 0.3765 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Alvotech SA | 308.73m | -618.38m | 3.34bn | 999.00 | -- | -- | -- | 10.81 | -2.65 | -2.65 | 1.28 | -2.27 | 0.312 | 1.80 | 3.66 | 309,038.00 | -62.49 | -- | -222.85 | -- | 48.79 | -- | -200.30 | -- | 0.1569 | -0.2323 | 2.04 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -54.80m | 3.39bn | 50.00 | -- | 6.41 | -- | -- | -0.9043 | -0.9043 | 0.00 | 8.28 | 0.00 | -- | -- | 0.00 | -11.08 | -- | -11.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -257.60m | 3.45bn | 152.00 | -- | 4.44 | -- | -- | -3.58 | -3.58 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -47.82 | -52.81 | -50.15 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Biohaven Ltd | 0.00 | -746.61m | 3.72bn | 239.00 | -- | 9.48 | -- | -- | -9.15 | -9.15 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -137.07 | -- | -176.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| TG Therapeutics Inc | 346.73m | 95.69m | 3.91bn | 300.00 | 42.08 | 22.02 | 40.79 | 11.27 | 0.6001 | 0.6001 | 2.29 | 1.15 | 1.11 | 0.4505 | 6.86 | 1,313,356.00 | 30.76 | -62.87 | 43.42 | -80.06 | 92.76 | -- | 27.60 | -405.03 | 2.83 | 8.21 | 0.3661 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 1.39m | -258.54m | 4.22bn | 290.00 | -- | 5.04 | -- | 3,049.44 | -3.77 | -3.77 | 0.0201 | 10.47 | 0.0023 | -- | 0.4157 | 4,775.86 | -41.16 | -42.53 | -44.29 | -45.36 | -- | -- | -18,257.91 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Immunovant Inc | 0.00 | -272.55m | 4.23bn | 207.00 | -- | 7.76 | -- | -- | -1.92 | -1.92 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -57.93 | -- | -64.54 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Arcellx Inc | 144.75m | -53.89m | 4.33bn | 130.00 | -- | 8.87 | -- | 29.91 | -1.05 | -1.05 | 2.84 | 9.08 | 0.2132 | -- | -- | 1,113,423.00 | -7.94 | -38.82 | -9.68 | -45.41 | -- | -- | -37.23 | -339.38 | -- | -- | 0.038 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Data as of Sep 20 2024. Currency figures normalised to Biohaven Ltd's reporting currency: US Dollar USD
46.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 7.05m | 7.46% |
| 1919 Investment Counsel LLCas of 30 Jun 2024 | 6.48m | 6.85% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 5.86m | 6.20% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 5.44m | 5.75% |
| Suvretta Capital Management LLCas of 30 Jun 2024 | 5.20m | 5.50% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 3.65m | 3.86% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 3.19m | 3.38% |
| RP Management LLC (Investment Management)as of 30 Jun 2024 | 2.94m | 3.11% |
| Farallon Capital Management LLCas of 30 Jun 2024 | 2.25m | 2.38% |
| Bellevue Asset Management AGas of 30 Jun 2024 | 2.04m | 2.16% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
